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1394 Abstracts November 2014devices placed by interventional radiology (OR, 2.577;95% CI, 1.41-4.68)
were associated with PICC-bloodstream infection. Catheter lumens were
strongly associated with this event (double lumen, OR 5.21; 95% CI,
2.46-11.04, and triple lumen, OR, 10.84; 95% CI, 4.38-26.82). With
multivariable analysis only hospital length of stay, ICU status, and number
of PICC lumens remained signiﬁcantly associated with PICC-bloodstream
infection. In fact, the HR for PICC lumens increases substantially over
time suggesting earlier time to infection among patients with multi-lumen
PICCs (HR, 4.08; 95% CI, 1.51-11.02, and HR, 8.52; 95% CI, 2.55-
28.49 for double- and triple-lumen devices, respectively).
Comment: Assuming patients are in the hospital and in the intensive
care unit only because they need to be, the only modiﬁable risk factor for
PICC-associated bloodstream infection appears to be the number of lumens
in the catheter placed. The data suggests the number of lumens should be
kept as low as possible and multilumen catheters should only be used when
absolutely necessary.
Pressure Control During Preparation of Saphenous Veins
Li FD, Eagle S, Brophy C, et al. JAMA Surg 2014;149:655-62.
Conclusions: During preparation of vein grafts, limiting vein graft
distension with a pressure release valve preserves endothelial integrity, and
reduces intimal hyperplasia.
Summary: Long-term patency of vein conduits in the arterial system
is limited because of vein graft failure largely secondary to loss of endothelial
coverage and intimal hyperplasia. LoGerfo in the early 1980’s identiﬁed that
integrity of vein grafts is at least partially a function of initial intimal and neo-
intima preservation in preparation of the vein graft (LoGerfo FW et al, Sur-
gery 1981;90:1015-24). Flushing vein grafts during preparation with
uncontrolled pressure can result in high intraluminal pressure which can
exceed 600 mmHg, and result in denudation of the endothelium and a sub-
sequent inﬂammatory response that may lead to intimal hyperplasia (Khaleel
MS et al, Ann Thorac Surg 2012;93:552-8). In this study the authors
sought to investigate if pressure distension during vein graft reparation leads
to endothelial injury and intimal thickening. The hypothesis was that by
limiting pressure during distension, neointimal thickening would be
reduced and would result in preservation of vascular function of the grafts.
A pressure limiting device that potentially can be integrated into current
distension techniques was utilized in this study. The authors collected seg-
ments of human saphenous veins (HSVs) in a university hospital from 13
patients undergoing CABG procedures immediately after harvest (unmanip-
ulated [UM]), after pressure distension (after distension [AD]), and after
typical intraoperative surgical graft preparation (after manipulation [AM]).
Porcine saphenous veins (PSVs) from 7 healthy research animals were sub-
jected to manual pressure distension with or without an in-line PRV that
prevented pressures of 140 mm Hg or greater. Endothelial function of
the HSVs and PSVs was determined in a muscle bath and endothelial integ-
rity was assessed and intimal thickening in PSVs evaluated after 14 days in
organ culture. The primary outcome measures were endothelial function
measured in force, converted to stress, and deﬁned as the percentage relax-
ation of maximal phenylephrine-induced contraction. Endothelial integrity
was assessed by immunohistologic examination. Neointeimal thickness
was measured by histomorphometric analysis. Pressure distension of HSVs
led to decreased mean (SEM) endothelial-dependent relaxation (5.3%
[2.3%] for AD patients vs 13.7% [2.5%] for UM patients; P < .05) and
denudation. In the AM group, the function of the conduits was further
decreased (-3.2% [3.2%]; P < .05). Distension of the PSVs led to reduced
endothelial-dependent relaxation (7.6% [4.4%] vs 61.9% [10.2%] in the con-
trol group; P < .05), denudation, and enhanced intimal thickening (15.0
[1.4] mm vs 2.2 [0.8] mm in the control group; P <.05). Distension with
the PRV preserved endothelial-dependent relaxation (50.3% [9.6%]; P ¼
.32 vs control, prevented denudation, and reduced intimal thickening
(3.4 [0.8] mm; P ¼ .56 vs controls) in PSVs.
Comment: In its entirety the data appears to demonstrate a causal
relationship between manual distension, endothelial, and medial injury,
and intimal hyperplasia. Assuming endothelial injury and intimal hyperplasia
have adverse effects on vein graph patency, it is possible the use of this sim-
ple pressure regulating valve employed in this study may help contribute to
long-term vein graft patency in both coronary and peripheral vascular
procedures.
Hemodynamic-Guided Fluid Administration for the Prevention of
Contrast-Induced Acute Kidney Injury: The POSEIDON
Randomized Controlled Trial
Brar SS, Aharonian V, Mansukhani P, et al. Lancet 2014;383:1814-23.
Conclusions: Left ventricular end-diastolic pressure-guided ﬂuid
administration is a safe and effective method to prevent contrast-induced
kidney injury in patients undergoing angiography.Summary: A common cause of acute kidney injury is contrast-
induced. This is associated with both increased morbidity, mortality and
health-care costs. There are no known treatments available after acute kid-
ney injury has occurred. Primary focus is therefore to identify preventative
therapies. Currently, although many interventions have been assessed to
prevent contrast-induced acute kidney injury, none are universally
embraced with the exception of intravascular volume expansion. However,
the rate and duration of ﬂuid administration around the time of contrast
exposure that could optimally prevent acute kidney injury is unclear. In
this study, the Prevention of Contrast Renal Injury with Different Hydra-
tion Strategies (POSEIDON) trial the authors investigated different rates
of ﬂuid administration guided by left ventricular end-diastolic pressure in
patients undergoing cardiac catheterization. This was a randomized, paral-
lel-group, comparator-controlled, single-blind phase 3 trial. The trial inves-
tigated the efﬁcacy of a new ﬂuid protocol based on left ventricular end-
diastolic pressure for the prevention of contrast-induced acute kidney injury
in patients undergoing cardiac catheterization. The primary outcome was
the occurrence of contrast-induced acute kidney injury, which was deﬁned
as an increase in serum creatinine concentration of greater than 25% of
baseline or greater than 0.5 mg/dL. Between October 10, 2010 and
July 17, 2012, 396 patients aged 18 years or older undergoing cardiac cath-
eterization with an estimated glomerular ﬁltration rate of 60 mL/min per
1.73 m2 or less and one or more of several risk factors (diabetes, history of
congestive heart failure, hypertension, or age older than 75 years) were
randomly allocated in a 1:1 ratio to left ventricular end-diastolic pressure-
guided volume expansion (n ¼ 196) or the control group (n ¼ 200)
who received a standard ﬂuid administration protocol. Four computer-
generated concealed randomization schedules, each with permuted block
sizes of 4, were used for randomization and participants were allocated
to the next sequential randomization number by sealed opaque envelopes.
Patients and laboratory personnel were masked to treatment assignment,
but the physicians who did the procedures were not masked. Both groups
received intravenous 0.9% sodium chloride at 3 mL/kg for 1 hour before
catheterization. Analyses were by intention to treat. Adverse events were
assessed at 30 days and 6 months and all such events were classiﬁed by staff
who were masked to treatment assignment. Findings concluded that
contrast-induced acute kidney injury occurred less frequently in patients
with left ventricular end-diastolic pressure-guided ﬂuid administration
(6.7% [12/178]) than in the control group (16.3% [28/172]; relative
risk, 0.41, 95% CI, 0.22-0.79; P ¼ .005). Hydration treatment was termi-
nated prematurely because of shortness of breath in three patients in each
group. The total mean (SD) volume of normal saline administered was
1727 (583) mL in the left ventricular end-diastolic pressure-guided group
vs 812 (142) ml in the control group (P < .001).
Comment: The study is possible because left ventricular end-diastolic
pressure is a haemodynamic parameter routinely obtained during cardiac
catheterization. Obviously that is not the case in angiographic procedures
performed for other reasons. Nevertheless, the fact patients who had end-
diastolic monitoring to guide their ﬂuid administration received larger vol-
umes of ﬂuid and had decreased levels of acute kidney injury compared to
the control group, implies that more aggressive hydration of patients at
the time of administration of contrast than is routinely performed could
be an effective strategy to reduce contrast-induced acute kidney injury.
Sex Differences in the Association Between Smoking and Abdominal
Aortic Aneurysm
Stackelberg O, Björck M, Larsson SC, et al. Br J Surg 2014;101:1230-7.
Conclusions: There are sex differences in the association between
smoking status and abdominal aortic aneurysm (AAA) risks. Further inves-
tigation of targeted AAA screening among women who smoke is indicated.
Summary: Ultrasound screening for AAA among men has been
demonstrated by randomized trials to be an effective strategy to prevent
rupture and aneurysm associated death. AAA is considered more dangerous
in women than men, but thus far there’s no randomized data supporting ul-
trasound screening among women for AAA. However, the Society for
Vascular Surgery and the European Society for Vascular Surgery have
both suggested that ultrasound screening in women as an effective strategy
to prevent aneurysm related death in women. It is known that smoking and
the risk of AAA is widely correlated and that smoking cessation is one of the
few medical strategies that can decrease the expansion and rupture
rate of small screen detected AAA (Sweeting MJ et al, Br J Surg
2012;99:655-65). In this study the authors sought to investigate sex spe-
ciﬁc, dose response associations between smoking (smoking status, pack-
years smoked, and smoking cessation) and risk of developing AAA in two
large, comparable, population-based prospective cohorts of women and
men from central Sweden. Women in the Swedish Mammography Cohort
and men in the Cohort of Swedish Men were followed up from 1998 to
2011. AAA was identiﬁed through linkage of the cohorts to the Swedish
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(Swedvasc). Associations were estimated with Cox proportional hazards
models. The cohorts included 35,550 women and 42,596 men, aged 46
to 84 years. During follow-up, AAA was identiﬁed in 199 women and
958 men. The incidence of AAA per 100,000 person-years was 76 among
men who never smoked and 136 among women who currently smoked.
Regarding AAA risk, women were more sensitive to current smoking
(P interaction ¼ .002). Compared with never smokers, the hazard ratio
(HR) for AAA in current smokers with more than 20 pack-years was
10.97 (95% conﬁdence interval [CI], 7.41-16.26) among women and
6.55 (95% CI, 5.36-7.99) among men. Following smoking cessation,
women had a more rapid decline in excess risk (P interaction < 0.001). The
risk was halved after 11 years (HR, 0.51; 95% CI, 0.32-0.81) among
women and after 23 years (HR, 0.50; 95% CI, 0.42-0.60) among men.
Comment: The data suggests that although women are not generally
included in AAA screening programs, women who smoke have a higher
incidence of AAA than men who never smoked. It also appears that women
are more sensitive to current tobacco exposure with regard to AAA risk and
that smoking cessation decreasing the risk of AAA twice as quickly among
women than men. It therefore appears that targeted screening for AAA in
women should be investigated further with both screening based studies
and cost-effectiveness analyses.
Vein Graft Preservation Solutions, Patency, and Outcomes After
Coronary Artery Bypass Graft Surgery: Follow-up From PREVENT
IV Randomized Clinical Trial
Harskamp RE, Alexander JH, Schulte PJ, et al. JAMA Surg 2014;149:
798-805.
Conclusions: Patients undergoing coronary artery bypass grafting
with vein grafts preserved in a buffered saline solution had lower graft failure
rates and trends toward better long-term clinical outcomes compared with
patients whose grafts were preserved in saline or blood-based solutions.
Summary: After harvesting a vein graft for implantation in the coro-
nary or peripheral circulation, the graft may be temporarily stored in a pres-
ervation solution. There’s great variation among hospitals and surgeons as
to the choice of preservation solution. Such solutions range from physio-
logic saline to autologous blood and to solutions that contain ions for pH
buffering, antioxidants, and ionic compositions similar to intracellular ﬂuid.
All solutions have not been compared in clinical trials. In this study the au-
thors performed an observational comparative-effectiveness evaluation of
various vein graft preservation solutions using data from the PREVENT
IV trial. This was a large randomized clinical trial of patients undergoing
CABG surgery. The patterns of vein graft preservation solutions in clinical
practice were delineated and vein graft failure rates at 1-year and long-
term clinical outcomes after CABG surgery among patients whose grafts
were treated with various preservation solutions were compared. PREVENT
IV was the coronary bypass parallel study of PREVENT III. Both were
phase 3, multicenter, randomized, double-blind, placebo-controlled trials,
of treatment of vein grafts with E2F transcription factor decoy edifoligide
in patients undergoing either peripheral vein graft bypass for lower extrem-
ity critical arterial ischemia (PREVENT III) or coronary artery bypass graft-
ing (PREVENT IV). PREVENT IV took place at 107 U.S. sites from
August 1, 2002 through October 22, 2003. To participate in PREVENT
IV, the patient needed to be undergoing CABG surgery with at least 2
planned vein grafts. In this study the vein grafts were stratiﬁed for whether
they were preserved in a saline, blood or buffered saline solution. The main
outcome measure was one-year angiographic vein graft failure and 5-year
rates of death, myocardial infarction, and subsequent revascularization. Sa-
line solution was the most common preservation solution (1339 [44.4%]
patients), followed by blood (971 [32.2%]), and buffered saline (507
[16.8%]). Baseline characteristics were similar among groups. One-year
vein graft failure rates were lower in the buffered saline group than in the
saline group (patient-level odds ratio, 0.59; 95% conﬁdence interval [CI],
0.45-0.78; P < .001; graft-level odds ratio, 0.63; 95% CI, 0.49-0.79;
P < .001) for the blood group (patient level odds ratio, 0.62; 95% CI,
0.46-0.83; P ¼ .001; graft level odds ratio, 0.63; 95% CI, 0.48-0.81;P < .001). Buffered saline solution also tended to be associated with a lower
5-year risk for death, myocardial infarction, or subsequent revascularization
compared with saline (hazard ratio, 0.81; 95% CI, 0.64-1.02; P ¼ .08) and
blood (0.81; 95% CI, 0.63-1.03; P ¼ .09) solutions.
Comment: One has to wonder if the physiologic pH and isotonic
milieu provided by buffered saline contributed to the observed vein reduc-
tion vein graft failure rates, why such a reduction was not seen with blood
based preservative as well. One must recognize the possibility of a number
of unaccounted for confounding variables such as degree of hydrostatic vein
graft distension, traction injury, among others that may have also contrib-
uted to this ﬁnding. In addition, clearly the ﬂow characteristics of the cor-
onary and peripheral circulations are not the same and one wonders
whether the data can truly be extrapolated to peripheral artery bypass sur-
gery. Perhaps a similar analysis with respect to peripheral bypass surgery
will be forthcoming from the PREVENT III investigators?
Statin Use and Rupture of Abdominal Aortic Aneurysm
Wemmelund H, Høgh A, Hundborg HH, et al. Br J Surg 2014;101:
966-75.
Conclusions: Statin use is associated with a reduced risk of rupture of
abdominal aortic aneurysm (AAA) and lower case fatality following rupture
of AAA.
Summary: There have been studies suggesting that statins may
reduce AAA growth rates and rupture risk by enhancing endothelial func-
tion and attenuating oxidative stress and inﬂammation of the vessel wall
(Liao JK. Am J Cardiol 2005;96:24F-33F). Meta-analyses also suggests
decreased growth rate of AAAs with the use of statins (Sweeting MJ et al,
Br J Surg 2012;99:655-65). In addition there have been small, single-center
observational studies suggesting an association between prehospital statin
therapy and lower mortality following surgery for ruptured (rAAA) (Feeney
JM et al, J Am Coll Surg 2009;209:41-6). In the current study the authors
use the Danish National Registry of Patients, to examine incident rAAA
cases and AAA control patients with a focus on the risk and prognosis of
rAAA. This was a nationwide, population-based, combined case-control
and follow-up study that included all patients (aged at least 50 years) with
a ﬁrst-time hospital admission for rAAA and 1:1 matched AAA controls
without rupture in Denmark, from 1996 to 2008. Individual-level data
on preadmission drug use, comorbidities, socioeconomic markers, health-
care contacts and death were obtained from nationwide registries. The study
included 3584 cases and 3584 match controls. Current statin use was regis-
tered for 418 patients with rAAA (11.7%) and 539 AAA controls (15.0%),
corresponding to an age- and sex-matched odds ratio of 0.7 (95% CI, 0.60-
0.81) for rAAA in current statin users vs never users. The decreased risk of
rAAA remained after adjustment for potential confounding factors (adjusted
OR, 0.73; 95% CI, 0.61-0.86). Overall, 30-day mortality rate from time of
hospital admission among patients with rAAA was 46.1% in current statin
users compared with 59.3% in never users (adjusted mortality rate
[MRR], 0.80, 95% CI, 0.68-0.95). Patients who had formerly used statins
did not have reduced mortality (adjusted MRR, 0.98; 95% CI, 0.78-1.22).
Comment: The study suggests beneﬁts for statins in patients with
AAA both in lower rupture rates and improved survival of ruptures. How-
ever, it has a number of signiﬁcant limitations in that there was no data
on AAA diameter, a known predictor of rupture. It may also be possible
that patients who use statins are more cooperative in adherence to medical
recommendations and have greater contact with a healthcare system, and
therefore are overall more healthy and have their aneurysms diagnosed at
a smaller size prior to rupture, where they can be ﬁxed electively. Neverthe-
less, given that patients with AAA generally have manifestations of athero-
sclerosis and vascular disease other than AAA that are considered to
beneﬁt from statins, there seems to be no downside to placing patients
with AAAs on a statin medication. Certainly additional analyses of possible
mechanism of beneﬁt are needed, but for the moment the results of this
study support current guidelines that recommend initiation of prophylactic
statin treatment in asymptomatic patients with AAA (Chaikof EL et al, J
Vasc Surg 2009;50(Suppl):S2-S49, and Moll FL, Eur J Vasc Endovasc
Surg 2011;41(Suppl 1):S1-S58).
